Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients.
BACKGROUND
Deregulation of Polycomb member Bmi-1 is involved in cell proliferation and human oncogenesis. Modulation of Bmi-1 is found in several tumor tissues, including primary breast carcinomas; however, analysis of Bmi-1 in plasma of cancer patients has not been reported. This is the first study that evaluates Bmi-1 in plasma by using a large series of primary breast carcinomas to investigate the presence at diagnosis of detectable Bmi-1 mRNA in plasma and possible correlations between this event and a series of clinical-pathological parameters of the tumors.


METHODS
Bmi-1 expression levels were quantified in plasma of 111 breast cancer patients and in 20 healthy controls by real-time quantitative polymerase chain reaction.


RESULTS
Cancer patients with the presence of Bmi-1 mRNA in plasma had higher levels of Bmi-1 expression than healthy controls with Bmi-1 mRNA in plasma. The higher expression levels of Bmi-1 correlated with well-established markers of poor clinical outcome in breast cancer such as positive p53 immunostaining and negative progesterone receptors. Moreover, we described for the first time a statistically significant correlation between Bmi-1 expression in plasma of breast cancer patients and disease-free and overall survival in advanced stages.


CONCLUSIONS
Our results suggest that levels of Bmi-1 expression may be a surrogate marker of poor prognosis and may become clinically useful as noninvasive diagnostic markers.
Silva
Javier
J
Department of Medical Oncology, Hospital Universitario Puerta de Hierro, C/San Martín de Porres, 4, E-28035 Madrid, Spain.
García
Vanesa
V
García
José M
JM
Peña
Cristina
C
Domínguez
Gemma
G
Díaz
Raquel
R
Lorenzo
Yolanda
Y
Hurtado
Alicia
A
Sánchez
Antonio
A
Bonilla
Félix
F
D014408:Biomarkers, Tumor / Q000235:genetics; D001943:Breast Neoplasms / Q000097:blood*; D018270:Carcinoma, Ductal, Breast / Q000097:blood*; D018275:Carcinoma, Lobular / Q000097:blood*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D009360:Neoplastic Cells, Circulating / Q000473:pathology*; D009687:Nuclear Proteins / Q000235:genetics*; D063150:Polycomb Repressive Complex 1; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D012333:RNA, Messenger / Q000097:blood*; D012334:RNA, Neoplasm / Q000235:genetics / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012097:Repressor Proteins / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015996:Survival Rate
D014408:Biomarkers, Tumor; D009687:Nuclear Proteins; D063150:Polycomb Repressive Complex 1; D011518:Proto-Oncogene Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D012097:Repressor Proteins; C069077:BMI1 protein, human
Cancer Res. 2001 Aug 1;61(15):5723-6
11479206
Clin Cancer Res. 1999 Aug;5(8):1961-5
10473072
Clin Cancer Res. 2001 Sep;7(9):2821-5
11555599
Nat Rev Mol Cell Biol. 2001 Oct;2(10):731-7
11584300
Gut. 2002 Apr;50(4):530-4
11889075
Cancer Res. 2002 Aug 15;62(16):4736-45
12183433
Genes Chromosomes Cancer. 2002 Dec;35(4):375-6
12378534
Clin Cancer Res. 2002 Dec;8(12):3761-6
12473587
Cancer Lett. 2004 Jan 20;203(2):217-24
14732230
Am J Pathol. 2004 Mar;164(3):873-81
14982841
Clin Cancer Res. 2004 Mar 1;10(5):1613-7
15014011
Nature. 2004 Mar 18;428(6980):337-41
15029199
Hepatology. 2004 Apr;39(4):944-53
15057898
Cell. 2004 Aug 20;118(4):409-18
15315754
Breast. 2004 Oct;13(5):383-8
15454193
Cancer Res. 1977 Mar;37(3):646-50
837366
Cancer. 1983 Jun 1;51(11):2116-20
6188527
J Natl Cancer Inst. 1996 Feb 21;88(3-4):173-82
8632491
Nat Med. 1996 Sep;2(9):1033-5
8782463
Gastroenterology. 1997 Apr;112(4):1114-20
9097993
Genes Chromosomes Cancer. 1999 Feb;24(2):160-1
9885984
Nature. 1999 Jan 14;397(6715):164-8
9923679
Cancer Res. 1999 Mar 15;59(6):1188-91
10096545
Cancer Res. 1999 Jul 1;59(13):3251-6
10397273
Clin Chem. 1999 Aug;45(8 Pt 1):1292-4
10430801
J Pathol. 2004 Dec;204(5):528-37
15470680
DNA Cell Biol. 2005 Feb;24(2):117-25
15699631
Hum Mol Genet. 2005 Apr 15;14 Spec No 1:R93-R100
15809278
Blood. 2006 Jan 1;107(1):305-8
16160010
Nucleic Acids Res. 2006;34(6):1745-54
16582100
Cancer Res. 2006 Jun 15;66(12):6225-32
16778197
Cell Cycle. 2006 Aug;5(16):1886-901
16963837
Clin Cancer Res. 2006 Dec 1;12(23):6929-36
17145810
Genes Dev. 1999 Oct 15;13(20):2678-90
10541554
Am J Pathol. 2000 Sep;157(3):709-15
10980109
Clin Cancer Res. 2000 Oct;6(10):3823-6
11051224
Cancer Res. 2001 Mar 15;61(6):2409-12
11289106
Lab Invest. 2001 May;81(5):767-9
11351048
Br J Cancer. 2001 May 18;84(10):1372-6
11355949
Blood. 2001 Jun 15;97(12):3896-901
11389032
Nat Rev Mol Cell Biol. 2001 Jun;2(6):409-21
11389465
J Clin Pathol. 2007 Feb;60(2):167-72
16837630
Clin Cancer Res. 2001 Aug;7(8):2222-7
11489795